Study: 82% Regain Weight After Stopping Mounjaro

Cardiometabolic parameter change by weight regain on tirzepatide withdrawal in adults with obesity

About The Study: In this post hoc analysis of the SURMOUNT-4 trial, among participants with obesity who achieved weight reduction with 36-week tirzepatide (a glucagon-like peptide-1 receptor agonist) treatment, withdrawing tirzepatide led to 25% or greater weight regain in most participants within 1 year and was associated with a greater reversal of their initial cardiometabolic parameter improvements compared with those who maintained weig…

Revealed: 2.5m Britons now use weight loss jabs

Jump in sales means one in 20 adults now taking fat-fighting medication as Health Secretary vows to increase access for less well off

1 in 8 Americans have already tried Ozempic and similar weight loss medications

GLP-1 drugs like Ozempic have transformed weight loss in the U.S., with nearly 12% of Americans having tried them, according to a new RAND report. Usage is especially high among women aged 50 to 64, while men catch up in older groups. Despite effectiveness, side effects like nausea and diarrhea are common, and most Americans say they don’t plan to take them.

Three key benefits reversed within months after patients discontinue Mounjaro, scientists warn

People who stop taking the weight-loss medication Mounjaro don't just pile the pounds back on - they also lose the cardiovascular benefits that came with shedding weight, new research has warned

Health benefits of Mounjaro reverse when jabs halted, study says

Researchers found benefits including reduced blood pressure were reversed after patients ceased taking the jab

Cardiometabolic Gains Backslide After Halting Obesity Meds

(MedPage Today) -- Weight regain after the withdrawal of tirzepatide (Zepbound) may wipe out many of the cardiometabolic gains made during weight loss, a post-hoc analysis of the SURMOUNT-4 trial indicated. Among 308 participants with obesity...